A Case Report of Parkinson’s Disease in a 70 year Man With Myasthenia Gravis

Muhammad Yanuar Ahadi, Deby Wahyuning Hadi, Soemarno Soemarno, Evi Octavia

Abstract


Abstract

Background:. Neurodegenerative diseases such as Parkinson’s disease (PD) have increasing incidence, due to lifespan expansion. The association between PD and Myasthenia Gravis (MG) is uncommon, and so far, since 1987, 26 cases have been reported.

Case presentation: This is a report of a 70-year-old man was referred into the hospital with ptosis, disfagia and dispnea. He was diagnosed with Suspected Myasthenia Gravis, Post Stroke Trombotik, Parkinson’s Disease and Hypertension. The patient was admitted to the outpatient unit, received of treatment Pyridostigmine, Clopidogrel, Trihexylphenidil, Vitamine B1, Vitaminie B6, Vitamine B12 and Levodopa-Benserazide .

Discussion: Treatment guidelines by using some guidelines are also drug doses and do not have adverse side reactions during treatment.

Conclusion:. PD and MG very rarely occur together. case report or a series of brief cases reported in the literature, it is very important not to miss the diagnosis of MG in patients with PD, because the treatment implications are very important and greatly influence the prognosis. More basic research needs to be done to understand the pathogenesis of both diseases, to provide more therapeutic options and possibly change the approach of the patient, whose quality of life is determined by these two neurological diseases, which have an increased impact on increasing disability

Key words: Parkinson disease; Myasthenia gravis; co‐occurrence; case report.


Full Text:

PDF

References


Connolly, B. S. and Lang, A. E. (2014) ‘Pharmacological Treatment of Parkinson Disease’, JAMA, 311(16), pp. 1670–1683. doi: 10.1001/jama.2014.3654.

Corbett, A. H. a. (2014) ‘Drug Information Handbook 23 rd Edition’. Lexicomp, p. 241.

Cornblath, W. T. (2018) ‘Treatment of ocular myasthenia gravis’, Asia-Pacific Journal of Ophthalmology, 7(4), pp. 257–259. doi: 10.22608/APO.2018301.

Guidelines, E. S. H. H. (2018) ‘2018 ESC-ESH Guidelines for the Management of Arterial Hypertension’, pp. 1953–2041.

Gupta, D. and Kuruvilla, A. (2011) ‘Vascular parkinsonism: what makes it different?’, Postgraduate Medical Journal, 87(1034), pp. 829 LP – 836. doi: 10.1136/postgradmedj-2011-130051.

Jost, W. H. and Brück, C. (2002) ‘Drug interactions in the treatment of Parkinson’s disease’, Journal of Neurology, Supplement, 249(3). doi: 10.1007/s00415-002-1305-0.

Kernan, W. N. et al. (2014) AHA / ASA Guideline Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. doi: 10.1161/STR.0000000000000024.

Lafaver, K. et al. (2019) ‘Comorbid Parkinson ’ s disease and Myasthenia Gravis : A Case-Control Study’, 34(suppl 2).

Levin, N., Karussis, D. and Abramsky, O. (2003) ‘Parkinson ’ s disease associated with myasthenia gravis’, pp. 766–767. doi: 10.1007/s00415-003-1088-y.

Li, M. et al. (2019) ‘Do early prednisolone and other immunosuppressant therapies prevent generalization in ocular myasthenia gravis in Western populations: a systematic review and meta-analysis’, Therapeutic Advances in Neurological Disorders, 12, pp. 1–8. doi: 10.1177/1756286419876521.

Malabaey, M. A. T. et al. (2019) ‘Pyridostigmine suicidal attempt in a myasthenia gravis patient’, American Journal of Case Reports, 20, pp. 1418–1421. doi: 10.12659/AJCR.917308.Odajiu, I. et al. (2020) ‘Patients with Parkinson ’ s Disease and Myasthenia Gravis — A Report of Three New Cases and Review of the Literature’. doi: 10.3390/medicina56010005.

Park, J. (2016) ‘Movement Disorders Following Cerebrovascular Lesion in the Basal Ganglia Circuit’, 9(2), pp. 71–79.

Seijo-Martinez, M. et al. (2011) ‘Prevalence of parkinsonism and Parkinson’s disease in the Arosa Island (Spain): A community-based door-to-door survey’, Journal of the Neurological Sciences, 304(1), pp. 49–54. doi: https://doi.org/10.1016/j.jns.2011.02.015.

Siniscalchi, A. et al. (2012) ‘Post-stroke Movement Disorders : Clinical Manifestations and Pharma- cological Management’, pp. 254–262.

Tanovska, N. et al. (2018) ‘Myasthenia Gravis and Associated Diseases’, pp. 1–7.

Tzartos, S. J. (2014) ‘Parkinson ’ s disease associated with myasthenia gravis and rheumatoid arthritis Parkinson ’ s disease associated with myasthenia gravis and rheumatoid arthritis’, JAMA, (March). doi: 10.1007/s10072-014-1660-5.

Urban, P. P. et. a. (2018) ‘Treatment Standards and Individualized Therapy of Myasthenia Gravis’, Neurology International Open, pp. 84–92. doi: https://doi.org/10.1055/s-0043-12498.

Williams-gray, C. H. (2016) ‘Parkinson ’ s disease Key points’, Medicine. Elsevier Ltd, 44(9), pp. 542–546. doi: 10.1016/j.mpmed.2016.06.001.

Xu, Y. et al. (2020) ‘Madopar combined with acupuncture improves motor and non-motor symptoms in Parkinson’s disease patients: A multicenter randomized controlled trial’, European Journal of Integrative Medicine. Elsevier, 34(December 2019), p. 101049. doi: 10.1016/j.eujim.2019.101049.




DOI: https://doi.org/10.18860/jip.v5i2.8813

Refbacks

  • There are currently no refbacks.


© 2019 Journal of Islamic Pharmacy - All rights reserved